Covalent BET Inhibitors

Zenith is leading in the contribution to the research and discovery of covalent inhibitors that irreversibly bind to their targets resulting in durable inhibition. This approach has the potential advantage of increased selectivity amongst BET proteins, along with generating longer lasting effects. Details of the characterization of the Zenith covalent BET inhibitor ZEN-3219 were published in the Journal of Medicinal Chemistry.